Greetings, Investors!
I simply did not see the news earlier this morning, as fixated as I was on getting that earlier email out and on other tasks.
But I subsequently saw THIS NEWS that came out at the market open: of a patient who passed away due to liver issues, while taking Sarepta Therapeutics’ (NASD-SRPT) gene therapy Elevidys.
In short: I concur with the piece highlighted by IBD‘s Allison Gatlin, an article from a few hours ago just updated.
So, BUY Sarepta once again, at least as a trade.
__________________________________________________________________
You “old hands” know that every now and then SRPT can gap big-time up (as mid-2024) or down (as today), usually as investors overreact alternately to either good or bad news.
Today seems to be the latter; and an opportunity yet again in this gift that keeps on giving, our single-best money maker EVER in The National Investor’s nearly three decade run.
Last check, SRPT was right about at $80 even, seeming to stabilize around there after an initial sell-off down to near $75. Anything in the low 80’s or less is good…
All the best,
Chris Temple
Editor/Publisher
Tuesday early afternoon — March 18, 2025
Don’t forget that you can follow my thoughts, focus and all pretty much daily ! ! !
* On Twitter, at https://twitter.com/NatInvestor
* On Facebook at https://www.facebook.com/TheNationalInvestor
* On Linked In at https://www.linkedin.com/in/chris-temple-1a482020/
* On my You Tube channel, at https://www.youtube.com/c/ChrisTemple (MAKE SURE TO SUBSCRIBE!)
When you join me, among the many things you’ll be entitled to is my “Members Handbook.” It crystallizes my approach to the markets…asset allocation recommendations… how I select individual companies…and a LOT more.
